| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/24/2005 | CA2535007A1 Nogo receptor antagonists |
| 02/24/2005 | CA2534950A1 Cyclic amine bace-1 inhibitors having a benzamide substituent |
| 02/24/2005 | CA2534932A1 Form of administration secured against misuse |
| 02/24/2005 | CA2534925A1 Dosage form that is safeguarded from abuse |
| 02/24/2005 | CA2534924A1 Novel metaxalone compositions |
| 02/24/2005 | CA2534922A1 Composition comprising a zeolite compound for treatment of diseases |
| 02/24/2005 | CA2534920A1 Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation |
| 02/24/2005 | CA2534897A1 Process of making flowable hemostatic compositions and devices containing such compositions |
| 02/24/2005 | CA2534887A1 Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds |
| 02/24/2005 | CA2534866A1 Piperazine derivatives for the treatment of hiv infections |
| 02/24/2005 | CA2534777A1 Sigma-1 receptor ligand with acetylcholinesterase inhibition properties |
| 02/24/2005 | CA2534729A1 Mitotic kinesin inhibitors |
| 02/24/2005 | CA2534300A1 Aminopyrones and their use as atm inhibitors |
| 02/24/2005 | CA2534047A1 Oxazoles derivatives, their manufacture and their use as tyrosine kinase inhibitors |
| 02/24/2005 | CA2533730A1 Methods for treatment of dermatological conditions |
| 02/24/2005 | CA2533638A1 Arylsulfonamidobenzylic compounds |
| 02/24/2005 | CA2532555A1 Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, aloe, and lemon oil |
| 02/24/2005 | CA2532553A1 Methods for identifying compounds for regulating muscle mass or function using dopamine receptors |
| 02/24/2005 | CA2532091A1 Methods for treating metabolic syndrome |
| 02/24/2005 | CA2531253A1 Sir2 regulation |
| 02/24/2005 | CA2530604A1 Combinatorial synthesis on support |
| 02/24/2005 | CA2529767A1 Aripiprazole and haloperidol pamoate salts |
| 02/24/2005 | CA2529750A1 N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| 02/24/2005 | CA2528938A1 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof |
| 02/24/2005 | CA2528519A1 Treatment of lung cancer with active vitamin d compounds in combination with other treatments |
| 02/24/2005 | CA2528192A1 Cristalline ziprasidone hcl and processes for preparation thereof |
| 02/24/2005 | CA2526339A1 Polyvalent immunogen |
| 02/24/2005 | CA2525670A1 Hair regenerator |
| 02/24/2005 | CA2525228A1 Molecules enhancing dermal delivery of influenza vaccines |
| 02/24/2005 | CA2524921A1 Method and composition for treating burned skin |
| 02/24/2005 | CA2524737A1 Antibodies that immunospecifically bind to trail receptors |
| 02/24/2005 | CA2518774A1 Heterocyclic n-aryl carboxamides as cytokine inhibitors |
| 02/24/2005 | CA2516425A1 Rna interference compositions and methods |
| 02/24/2005 | CA2500358A1 Probes for diseases in which amyloid accumulates, agents for staining amyloid, drugs for treatment and prophylaxis of diseases with accumulated amyloid, and probes for diagnosis of neurofibrillary tangles and agents for staining neurofibrillary tangles |
| 02/24/2005 | CA2497198A1 Agents and methods for treatment of disease by oligosaccharide targeting agents |
| 02/23/2005 | EP1508601A1 Cyanoacrylate compositions containing anti-microbial agent |
| 02/23/2005 | EP1508570A1 Novel physiolgically active substances |
| 02/23/2005 | EP1508561A1 2-(a-HYDROXYPENTYL) BENZOATE AND ITS PREPARATION AND USE |
| 02/23/2005 | EP1508340A1 Insulin resistance improving agents |
| 02/23/2005 | EP1508335A1 Composition against periodontal bacteria and foods, drinks and mouth washers against periodontal bacteria containing the composition |
| 02/23/2005 | EP1508333A1 Novel therapeutic use of riboside of 5-aminoimidazole-4- carboxamide (acadesine) |
| 02/23/2005 | EP1508332A1 Medicinal composition |
| 02/23/2005 | EP1508331A1 Method for preparing polymer micelle pharmaceutical preparation containing drug for injection |
| 02/23/2005 | EP1508330A1 Inhalation capsules |
| 02/23/2005 | EP1508328A1 Composition against the degradation of fibres of collagen induced in condition of natural solar exposure |
| 02/23/2005 | EP1508327A1 Use of chromen-4-one derivatives for the care of skin and hair |
| 02/23/2005 | EP1508043A2 Antigenic targets of autoimmune sensorineural hearing loss (aisnhl) and development of tests fro diagnosis and management of aisnhl |
| 02/23/2005 | EP1507874A2 Compositions and processes for inhibiting gene expression using polynucleotides |
| 02/23/2005 | EP1507873A1 Parallel stranded duplexes of deoxyribonucleic acid and methods of use |
| 02/23/2005 | EP1507855A2 Elongase genes and uses thereof |
| 02/23/2005 | EP1507847A2 Treatments with autologous fibroblast |
| 02/23/2005 | EP1507826A2 Amelioration of the development of cataracts and other opthalmic diseases |
| 02/23/2005 | EP1507813A1 Fat binding using inter-polymer complex of glucosamine and polyacrylic acid |
| 02/23/2005 | EP1507791A2 Antisense antiviral agent and method for treating ssrna viral infection |
| 02/23/2005 | EP1507781A2 Process for preparing maytansinol |
| 02/23/2005 | EP1507780A1 Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| 02/23/2005 | EP1507779A1 Inhibitors of jak and cdk2 protein kinases |
| 02/23/2005 | EP1507778A1 Anti-tumour polycyclic carboxamides |
| 02/23/2005 | EP1507776A1 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders |
| 02/23/2005 | EP1507775A1 Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
| 02/23/2005 | EP1507774A1 Processes for preparation of polymorphic forms of desloratadine |
| 02/23/2005 | EP1507773A1 Macrocyclic compounds useful as pharmaceuticals |
| 02/23/2005 | EP1507772A1 Methods of using thiazolidinedithione derivatives |
| 02/23/2005 | EP1507767A1 4-substituted imidazole-2-thiones and imidazol-2-ones as agonists of the alpha-2b and alpha-2c adrenergic receptors |
| 02/23/2005 | EP1507765A2 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| 02/23/2005 | EP1507764A1 Novel enantiomers of tetrahydroisoquinoline derivatives and their pharmaceutically acceptable salts, their preparations and pharmaceutical compositions |
| 02/23/2005 | EP1507762A1 Pesticidal pyridinecarboxamide derivatives |
| 02/23/2005 | EP1507761A1 Pyridine carboxamide derivatives and their use as pesticides |
| 02/23/2005 | EP1507760A1 Cyanoguanidine prodrugs |
| 02/23/2005 | EP1507759A1 Cyanoguanidine produgs |
| 02/23/2005 | EP1507758A2 Indole derivatives and their use as ligands for cb2 receptors |
| 02/23/2005 | EP1507757A1 Lactams used as anti-viral agents |
| 02/23/2005 | EP1507756A1 Ccr9 inhibitors and methods of use thereof |
| 02/23/2005 | EP1507754A1 Alkoxy aryl beta-2 adrenergic receptor agonists |
| 02/23/2005 | EP1507573A1 Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer |
| 02/23/2005 | EP1507559A1 Delivery of microparticle-conjugated drugs for inhibition of stenosis |
| 02/23/2005 | EP1507558A1 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| 02/23/2005 | EP1507555A2 Induction of antigen specific immunologic tolerance |
| 02/23/2005 | EP1507554A1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| 02/23/2005 | EP1507549A2 Drug therapy for celiac sprue |
| 02/23/2005 | EP1507544A1 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 02/23/2005 | EP1507542A2 Anti-cancer formulation |
| 02/23/2005 | EP1507541A2 Inhibitors and methods of use thereof |
| 02/23/2005 | EP1507539A1 Hormone replacement therapy using a combination of conjugated estrogens and trimegestone |
| 02/23/2005 | EP1507538A1 Norethindrone sustained release formulations and methods associated therewith |
| 02/23/2005 | EP1507537A1 Combination of an ace inhibitor, a calcium channel blocker and a diuretic |
| 02/23/2005 | EP1507536A2 Compositions and their uses for alleviating pain |
| 02/23/2005 | EP1507535A1 Pyrimidine-2,4,6-trione metallo-proteinase inhibitors |
| 02/23/2005 | EP1507534A2 Compounds, compositions and methods |
| 02/23/2005 | EP1507533A2 Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins |
| 02/23/2005 | EP1507532A2 Use of quinoline derivatives with anti-integrase effect and applications thereof |
| 02/23/2005 | EP1507531A2 Stable pharmaceutical compositions of desloratadine |
| 02/23/2005 | EP1507530A1 Diaminothiazoles |
| 02/23/2005 | EP1507529A1 Combination of organic compounds |
| 02/23/2005 | EP1507528A2 Methods for using jnk inhibitors for treating or preventing disease-related wasting |
| 02/23/2005 | EP1507527A2 Methods for enhancing motor performance and/or endurance |
| 02/23/2005 | EP1507525A1 Non-steroidal anti-androgen therapy |
| 02/23/2005 | EP1507524A1 Use of diuretics for treating swellings |
| 02/23/2005 | EP1507523A1 Cinnamic acid dimers, their preparation and the use thereof for treating neurodegenerative disease |
| 02/23/2005 | EP1507522A2 Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac |